Recce Pharmaceuticals Ltd (RCE.AX)
- GlobeNewswire
Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development
Inclusion underscores significance of RECCE® 327 (R327) in combating antimicrobial resistance and its potential to treat broad range of life-threatening and resistant bacteriaSYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced its primary anti-infective candidate, RECCE® 327 (R327), has been added to the World Health Organization’s (WHO) list of Antibacterial Agent
- GlobeNewswire
Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion Trial
Six additional participants intravenously dosed with RECCE® 327 (R327) at 4,000mg over 20 minutes – highest dosage to date in this trialSYDNEY, June 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX:RCE, FSE:R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it completed dosing an additional cohort in its Phase I/II UTI/Urosepsis trial, evaluating RECCE® 327 (R327) at fast infusion rates. "We have successfully reached a new milestone
- GlobeNewswire
Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial
First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future - 4,000mg highest dosage to date in this clinical trialRECCE® 327 (R327) tested at four fast IV infusion times (15-mins, 20-mins, 30-mins, 45-mins) over various dosage levelsMinimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples, a dose optimization exercise for regulatory purposes SYDNEY, Australia, May 17, 2024 (G
